New asthma drug candidate enters first human safety tests

NCT ID NCT07660731

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-stage study tests a new experimental drug, PF-08103402, for the first time in people. It includes healthy adults and adults with mild-to-moderate asthma to check safety, how the drug moves through the body, and whether food affects its absorption. Participants take the drug by mouth as a liquid or tablet, with some groups receiving it daily for up to 14 days. The study also looks at how the drug interacts with another medicine and how it is broken down and eliminated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-08103402
What this could lead to: If safe and well-tolerated, this could pave the way for larger studies to see if PF-08103402 helps control asthma symptoms.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or not work for asthma. Results in healthy people may not apply to those with asthma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA HEALTHY ADULTS HEALTHY PARTICIPANTS HEALTHY VOLUNTEER STUDY

Contacts and locations

Locations

Pfizer Clinical Research Unit - New Haven
RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.